Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Dysregulation of brain iron homeostasis is central to early neuropathological events in Alzhei mer's disease (AD), including oxidative stress, inflam matory processes, amyloid deposition, tau phosphory lation, and neuronal cell cycle regulatory failure, leading to apoptosis. Also, there is a direct link between iron metabolism and AD pathogenesis, demonstrated by the presence of an iron‐responsive element in the 5′ UTR of the amyloid precursor protein transcript. As a consequence of these findings, a new paradigm is emerging that includes the development of iron‐chelating neuroprotective‐neurorescue drugs with multimo dal functions, acting at various pathological brain tar gets. This concept is challenging the widely held assumption that “silver bullet” agents are superior to “dirty drugs” in drug therapy for neurodegenerative diseases. At best, the so‐called magic bullets exhibit moderate symptomatic activity without modifying the course of disease progression. The present review elaborates on conventional and novel therapeutic tar gets of various multifunctional iron‐chelating drugs ( e.g., chemically designed compounds; natural polyphe nols) that address multiple central nervous system etiologies in AD, aimed at preventing or slowing disease evolution. A similar approach in drug design is being investigated for treatment of cancer, AIDS, cardiovas cular diseases, and depression.—Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H. Mandel, S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J . 22, 1296–1305 (2008)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The benefits of administration of desferrioxamine in Alzheimer’s, for instance, have been known for nearly 20 years (Crapper McLachlan et al. 1991), benefits since observed with other iron chelators”
Citations
Cites
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“Both extracellular amyloid plaques and intracellular NFTs are central pathological hallmarks of AD (33).”
BackgroundYang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Iron, brain ageing and neurodegenerative disorders
Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R., & Crichton, R. R. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1537 · Cited by 1,801
Self-citationCherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447 · cited 1×
“burden and slowed the rate of cognitive decline (8).”
BackgroundMitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367 · cited 1×
“drial abnormalities (55); activation of select signal”
Iron accumulation in Alzheimer disease is a source of redox-generated free radicals
Smith, M. A., Harris, P. L. R., Sayre, L. M., & Perry, G. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9866 · Cited by 1,355
The metallobiology of Alzheimer's disease
Bush, A. I. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(03)00067-5 · Cited by 1,315
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 1×
“reduction in plasma amyloid-beta (A ) peptide A (1–42) and cognitive decline in AD patients (7), while in trans-”
BackgroundTargeting Multiple Signaling Pathways by Green Tea Polyphenol (−)-Epigallocatechin-3-Gallate
Khan, N., Afaq, F., Saleem, M., Ahmad, N., & Mukhtar, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3636 · Cited by 820
Intramuscular desferrioxamine in patients with Alzheimer's disease
MCLACHLAN, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)92978-b · Cited by 764
Cited by
Advances in metal-induced oxidative stress and human disease
Jomova, K., & Valko, M. (2011) · Toxicology · doi:10.1016/j.tox.2011.03.001 · Cited by 3,207
“In conclusion, considring the multiple iron-operating sites in Alzheimer’s disease, ron chelators, possessing several active neuroprotective moieties an suppress the wide spectrum of oxidative stress-associated europathologies, aswell as amyloidprecursor protein (APP) transation, A generation, and amyloid plaque and n…”
BackgroundTargeting Free Radicals in Oxidative Stress-Related Human Diseases
Poprac, P., Jomova, K., Simunkova, M., Kollar, V., Rhodes, C. J., & Valko, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.005 · Cited by 1,107
“This group has incorporated structural features of both rivastigmine and donepezil into a bifunctional chelator HLA20 [5-(4-propargylpiperazin-1-ylmethyl)-8-hydroxyquinol] in which the carbamoyl moiety of rivastigmine acts a protective group to mask the quinolinol oxygen playing an important role in metal chelation [9…”
BackgroundIron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics
Belaidi, A. A., & Bush, A. I. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13425 · Cited by 578
“3), which can be reversed using iron chelators (Yamamoto et al. 2002; Lovell et al. 2004; Chan and Shea 2006; Amit et al. 2008).”
BackgroundKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
“Iron (and in some cases copper) is also strongly implicated in a variety of neurodegenerative diseases [867] [868] [869] [870] [871] [872] [836] [873] [837] [850] [874] [875] [876] [877] [854] [878] [879] [880] [881] [842] [882] [883] [884] [885] [886] [887] [888] [889] [890] [891] [892] [893] [894] [895] [896] [897]…”
Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration
Masaldan, S., Bush, A. I., Devos, D., Rolland, A. S., & Moreau, C. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.033 · Cited by 481
“These events can be mitigated through iron chelation [2,201].”
Williams, R. J., & Spencer, J. P. E. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.09.010 · Cited by 448
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
A delicate balance: Iron metabolism and diseases of the brain
Hare, D., Ayton, S., Bush, A., & Lei, P. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00034 · Cited by 443
Copper, zinc and iron in neurodegenerative diseases (Alzheimer's, Parkinson's and prion diseases)
Kozlowski, H., Luczkowski, M., Remelli, M., & Valensin, D. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.013 · Cited by 437
Vauzour, D. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/914273 · Cited by 424
Smith, M. A., Zhu, X., Tabaton, M., Liu, G., McKeel, D. W., Cohen, M. L., Wang, X., Siedlak, S. L., Dwyer, B. E., Hayashi, T., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1239 · Cited by 401
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
“…in Alzheimer’s, for instance, have been known for nearly 20 years (Crapper McLachlan et al. 1991), benefits since observed with other iron chelators (e.g. Amit et al. 2008; Bolognin et al. 2009a; Bush 2008; Liu et al. 2009b, 2010b; Perez and Franz 2010; Smith et al. 2010; Zhang et al. 2009).”
BackgroundMetallostasis in Alzheimer's disease
Ayton, S., Lei, P., & Bush, A. I. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.10.558 · Cited by 352
“ing of Fe(III), but not Fe(II), induces an aggregation of hyperphosphorylated tau that can be reversed by reducing Fe(III) to Fe(II) [244] or with iron chelators [245].”
BackgroundPotential neuroprotective properties of epigallocatechin-3-gallate (EGCG)
Singh, N. A., Mandal, A. K. A., & Khan, Z. A. (2015) · Nutrition Journal · doi:10.1186/s12937-016-0179-4 · Cited by 314
Iron and Alzheimer’s Disease: From Pathogenesis to Therapeutic Implications
Liu, J.-L., Fan, Y.-G., Yang, Z.-S., Wang, Z.-Y., & Guo, C. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00632 · Cited by 284
“In addition to Aβ peptides, iron can bind to tau protein, induce tau protein phosphorylation, and aggregate phosphorylated tau protein, whereas this phenomenon can be reversed by iron chelators (Amit et al., 2008).”
BackgroundImportance of Iron Chelation in Free Radical-Induced Oxidative Stress and Human Disease
Jomova, K., & Valko, M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798072463 · Cited by 271
Schrag, M., Mueller, C., Oyoyo, U., Smith, M. A., & Kirsch, W. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.05.001 · Cited by 263
Potì, F., Santi, D., Spaggiari, G., Zimetti, F., & Zanotti, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020351 · Cited by 253
“This effect is likely to be responsible, at least in part, for the neuroprotective effective of some flavonoids [79].”
BackgroundSingh, N., Haldar, S., Tripathi, A. K., Horback, K., Wong, J., Sharma, D., Beserra, A., Suda, S., Anbalagan, C., Dev, S., et al. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4931 · Cited by 208
“VK28 is an antioxidant-iron chelating agent with the 8HQ moiety that protects against MPTP-and 6-OHDA-induced lesions in rat brains (14, 267).”
Xie, S.-S., Wang, X.-B., Li, J.-Y., Yang, L., & Kong, L.-Y. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.03.051 · Cited by 159
Bolea, I., Gella, A., & Unzeta, M. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-012-0948-y · Cited by 158
“Interestingly, M30 (12) inhibits the Ab aggregation induced by metals and reduces Ab formation (Amit et al. 2008; Avramovich-Tirosh et al. 2007).”
BackgroundMulti-Target Directed Donepezil-Like Ligands for Alzheimer's Disease
Unzeta, M., Esteban, G., Bolea, I., Fogel, W. A., Ramsay, R. R., Youdim, M. B. H., Tipton, K. F., & Marco-Contelles, J. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00205 · Cited by 144
“As mentioned above, iron also binds to tau protein, but only Fe3+ has reported to induce aggregation of hyperphosphorylated tau protein, which can be reversed by reducing Fe3+ to Fe2+ (Yamamoto et al., 2002) or by the use of iron-chelators (Amit et al., 2008).”
BackgroundSelf-citationIron Homeostasis Disorder and Alzheimer’s Disease
Peng, Y., Chang, X., & Lang, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212442 · Cited by 153
“At present, the most commonly used chelating agents are deferoxamine, deferrone and ferrite [2,134,135].”
BackgroundZheng, H., Youdim, M. B. H., & Fridkin, M. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900504c · Cited by 140
Self-citationDesign of iron chelators with therapeutic application
Zhou, T., Ma, Y., Kong, X., & Hider, R. C. (2012) · Dalton Transactions · doi:10.1039/c2dt12159j · Cited by 136
Vauzour, D. (2014) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.6473 · Cited by 135
Hydroxypyridinones as “privileged” chelating structures for the design of medicinal drugs
Santos, M. A., Marques, S. M., & Chaves, S. (2011) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2011.08.008 · Cited by 146
Polyphenols Beyond Barriers: A Glimpse into the Brain
Figueira, I., Menezes, R., Macedo, D., Costa, I., & dos Santos, C. N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666161026151545 · Cited by 128
“Catechins increased neuronal viability by modulation of signal transduction pathways, cell survival genes and mitochondria functions [reviewed in [159, 160], reduction of neurotoxins, and Aβ toxicity in several cell lines and primary cultures (Table 2).”
Siddiq, A., Aminova, L. R., Troy, C. M., Suh, K., Messer, Z., Semenza, G. L., & Ratan, R. R. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1779-09.2009 · Cited by 127
“…in stroke, Friedreich’s ataxia, Parkinson’s disease, and spinal cord injury (Cleland et al., 1982; Whitnall and Richardson, 2006; Petri et al., 2007; Amit et al., 2008; Blat et al., 2008; Forni et al., 2008; Kakhlon et al., 2008; Ratan et al., 2008; Weinberg and Miklossy, 2008; Xu et al., 2005;…”
BackgroundKupershmidt, L., Weinreb, O., Amit, T., Mandel, S. A., Carrì, M. T., & Youdim, M. B. H. (2009) · The FASEB Journal · doi:10.1096/fj.09-130047 · Cited by 129
“Indeed, many cell-cycle-regulating factors require iron for their function (46, 64), suggesting that cell-cycleblocking activity of iron chelators may trigger the process of differentiation through various ironassociated biological events (65).”
BackgroundSelf-citationWang, Z., Wang, Y., Wang, B., Li, W., Huang, L., & Li, X. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01222 · Cited by 117
Wang, Z., Wang, Y., Li, W., Mao, F., Sun, Y., Huang, L., & Li, X. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500119g · Cited by 115
Flanagan, E., Müller, M., Hornberger, M., & Vauzour, D. (2018) · Current Nutrition Reports · doi:10.1007/s13668-018-0226-1 · Cited by 115
Youdim, M. B. H. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1942-9 · Cited by 120
Self-citationMultifunctional Neuroprotective Derivatives of Rasagiline as Anti-Alzheimer's Disease Drugs
Weinreb, O., Mandel, S. A., Bar‐Am, O., Yogev‐Falach, M., Avramovich‐Tirosh, Y., Amit, T., & Youdim, M. B. H. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.030 · Cited by 121
Self-citationCellular Senescence and Iron Dyshomeostasis in Alzheimer’s Disease
Masaldan, S., Belaidi, A. A., Ayton, S., & Bush, A. I. (2019) · Pharmaceuticals · doi:10.3390/ph12020093 · Cited by 102
“These events can be mitigated by the chelation of iron [49].”
BackgroundNeurodegenerative diseases linked to misfolded proteins and their therapeutic approaches: A review
Khanam, H., Ali, A., Asif, M., & Shamsuzzaman (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.08.006 · Cited by 108
Zheng, H., Youdim, M. B. H., & Fridkin, M. (2010) · ACS Chemical Biology · doi:10.1021/cb900264w · Cited by 108
Self-citationMao, F., Yan, J., Li, J., Jia, X., Miao, H., Sun, Y., Huang, L., & Li, X. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00998c · Cited by 99
Advances in iron chelation: an update
Heli, H., Mirtorabi, S., & Karimian, K. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.569493 · Cited by 103
“Potential application of multimodal iron chelators as neuroprotective--neurorescue drugs in the prevention and treatment of neurodegenerative diseases has attracted a great deal of attention in recent years for at least three reasons [424,425].”
BackgroundThe role of glycogen synthase kinase 3 in the early stages of Alzheimers’ disease
Hernández, F., & Avila, J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.026 · Cited by 85
“The generation of ROS can be modulated by the presence of certain metals, like iron, that might accumulate in the brain with age [53].”
BackgroundChaudhaery, S. S., Roy, K. K., Shakya, N., Saxena, G., Sammi, S. R., Nazir, A., Nath, C., & Saxena, A. K. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100573q · Cited by 92
The potential application of iron chelators for the treatment of neurodegenerative diseases
Hider, R. C., Roy, S., Ma, Y. M., Le Kong, X., & Preston, J. (2011) · Metallomics · doi:10.1039/c0mt00087f · Cited by 83
Copper and iron in Alzheimer's disease: a systematic review and its dietary implications
Loef, M., & Walach, H. (2011) · British Journal Of Nutrition · doi:10.1017/s000711451100376x · Cited by 95
“For instance, ethylenediaminetetraacetic acid has been reported to induce improvement in patients with AD((182)).”
BackgroundZhang, C., Du, Q.-Y., Chen, L.-D., Wu, W., Liao, S., Yu, L., & Liang, X. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.077 · Cited by 91
Tea Polyphenols in Parkinson’s Disease
Caruana, M., & Vassallo, N. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-18365-7_6 · Cited by 97
“(i) anti-oxidant and anti-chelating activities; (ii) inhibition of as aggregation; and (iii) modulation of cell signalling pathways (Pan et al. 2003; Higdon and Frei 2003; Amit et al. 2008), which will be reviewed in the next sections.”
BackgroundUddin, M. S., Al Mamun, A., Kabir, M. T., Ashraf, G. M., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02116-9 · Cited by 86
Kupershmidt, L., Weinreb, O., Amit, T., Mandel, S. A., Bar‐Am, O., & Youdim, M. B. H. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.03.040 · Cited by 85
“…potential neuroprotective effects in preclinical neurodegenerative models with distinct etiologies, exerting selective iron chelation potency (compared with zinc and copper), radical scavenging, and inhibition of iron-induced membrane lipid peroxidation (Zheng et al., 2005a; Amit et al., 2008).”
BackgroundSelf-citationRecent Progress in Repositioning Alzheimer'S Disease Drugs Based on a Multitarget Strategy
Santos, M. A., Chand, K., & Chaves, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0103 · Cited by 78
Metallobiology of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity
Hare, D. J., Adlard, P. A., Doble, P. A., & Finkelstein, D. I. (2013) · Metallomics · doi:10.1039/c2mt20164j · Cited by 78
Iron chelation and neuroprotection in neurodegenerative diseases
Li, X., Jankovic, J. J., & Le, W. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0518-0 · Cited by 78
“2007); (3) targeting cell cycle reentry-initiated apoptosis (Avramovich-Tirosh et al. 2007; Amit et al. 2008; Gal et al. 2010); and by (4) promoting survival pathways though elevation of the pro-survival protein kinase C (PKC) isoforms (Reznichenko et al.”
BackgroundGal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2009) · Neurotoxicity Research · doi:10.1007/s12640-009-9070-9 · Cited by 76
“In fact, a novel therapeutic strategy for neurodegenerative disease, similar to cancer drug therapy, is currently directed at interfering with mitogenic signaling and cell cycle progression to ameliorate cell death (for a comprehensive review see Amit et al. (2007), Avramovich-Tirosh et al. (2007)).”
BackgroundSelf-citationValverde-Salazar, V., Ruiz-Gabarre, D., & García‐Escudero, V. (2023) · Antioxidants · doi:10.3390/antiox12071460 · Cited by 85
Bartzokis, G., Lu, P. H., Tishler, T. A., Peters, D. G., Kosenko, A., Barrall, K. A., Finn, J. P., Villablanca, P., Laub, G., Altshuler, L. L., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1368 · Cited by 69
Naoi, M., & Maruyama, W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.68 · Cited by 72
Parmar, T., Gadkar, S., Savardekar, L., Katkam, R. R., Dharma, S., Meherji, P. K., Puri, C. P., & Sachdeva, G. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.07.1734 · Cited by 68
“Iron appears to be a critical requirement for proliferation as iron-deprived cells fail to proceed from the G1 to the S phase of the cell cycle (19).”
BackgroundTransferrin and HFE genes interact in Alzheimer's disease risk: the Epistasis Project
Lehmann, D. J., Schuur, M., Warden, D. R., Hammond, N., Belbin, O., Kölsch, H., Lehmann, M. G., Wilcock, G. K., Brown, K. S., Kehoe, P. G., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.07.018 · Cited by 68
“, 2009) or iron helation (Amit et al., 2008; Crapper McLachlan et al., 991; Perez and Franz, 2010), might benefit elderly people ith these genetic combinations and needs to be explored urther.”
Mao, F., Huang, L., Luo, Z., Liu, A., Lu, C., Xie, Z., & Li, X. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.07.045 · Cited by 63
Chakrabarti, S., Sinha, M., Thakurta, I., Banerjee, P., & Chattopadhyay, M. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990152 · Cited by 63
Mechanisms of Intranasal Deferoxamine in Neurodegenerative and Neurovascular Disease
Kosyakovsky, J., Fine, J. M., Frey, W. H., & Hanson, L. R. (2021) · Pharmaceuticals · doi:10.3390/ph14020095 · Cited by 67
“In the absence of measures for complete prevention or regeneration of lost brain function, so-called “dirty drugs” that operate on multiple events in these pathogenic cascades may be the only realistic future for meaningful benefit in these diseases, such as Alzheimer’s disease [88].”
BackgroundLenhart, J. A., Ling, X., Gandhi, R., Guo, T. L., Gerk, P. M., Brunzell, D. H., & Zhang, S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100601q · Cited by 60
Zhu, J., Xia, R. M., Liu, Z., Shen, J., Gong, X., Hu, Y., Chen, H., Yu, Y., Gao, W., Wang, C., et al. (2019) · Chemosphere · doi:10.1016/j.chemosphere.2019.125336 · Cited by 59
Novel drug targets based on metallobiology of Alzheimer's disease
Bandyopadhyay, S., Huang, X., Lahiri, D. K., & Rogers, J. T. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.525352 · Cited by 63
“The metal chelating drugs DFO (Figure 4B), tetrathiolmolybdate (Figure 4F), and dimercaptopropanol (Figure 4G) [47,216] have shown a significant effect on Ab metabolism in vitro and/ or in vivo.”
BackgroundXu, Y. X., Zhang, Y., Zhang, J.-H., Han, K., Zhang, X., Bai, X., You, L., Yu, P., Shi, Z., Chang, Y.-Z., et al. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.07.012 · Cited by 58
Zhou, X., Li, Y., Shi, X., & Ma, C. (2016) · PubMed Central · Cited by 75
Molecular mechanisms of the neuroprotective neurorescue action of multi-target green tea polyphenols
Mandel, S. A., Weinreb, O., Amit, T., & Youdim, M. B. H. (2012) · Frontiers in Bioscience-Scholar · doi:10.2741/s286 · Cited by 60
Self-citationWeinreb, O., Mandel, S. A., Bar‐Am, O., & Amit, T. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0597-6 · Cited by 54
Self-citationZheng, H., Youdim, M. B. H., & Fridkin, M. (2010) · ACS Chemical Neuroscience · doi:10.1021/cn100069c · Cited by 52
Self-citationWong, B. X., & Duce, J. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00081 · Cited by 49
“…has yet to be established tau, binding of Fe 2 + appears to preferentially induce phosphorylation of tau (Lovell et al., 2004; Chan and Shea, 2006) despite 3 + being the favored state in causing aggregation of tau once it been hyperphosphorylated (Yamamoto et al., 2002; Amit et al., 2008).”
BackgroundMa, F., & Du, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.09.008 · Cited by 51
The roles of iron and HFE genotype in neurological diseases
Kim, Y., & Connor, J. R. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100867 · Cited by 48
Kakhlon, O., Breuer, W., Munnich, A., & Cabantchik, Z. I. (2010) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y09-128 · Cited by 48
Gaeta, A., Molina‐Holgado, F., Kong, X. L., Salvage, S., Fakih, S., Francis, P. T., Williams, R. J., & Hider, R. C. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.12.007 · Cited by 49
Vauzour, D. (2017) · OCL · doi:10.1051/ocl/2017008 · Cited by 51
Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice
Kupershmidt, L., Amit, T., Bar‐Am, O., Youdim, M. B. H., & Weinreb, O. (2012) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2012.03.001 · Cited by 40
Self-citationGetting the iron out: Phlebotomy for Alzheimer’s disease?
Dwyer, B. E., Zacharski, L. R., Balestra, D. J., Lerner, A. J., Perry, G., Zhu, X., & Smith, M. A. (2009) · Medical Hypotheses · doi:10.1016/j.mehy.2008.12.029 · Cited by 35
“The potential importance of iron-mediated oxidative stress/free radical damage in the development and progression of AD is underscored by efforts to develop iron chelators as therapeutic agents for AD [81,82].”
BackgroundVaz, G. R., Falkembach, M., Batista, M. M., Barros, P. A. B., Oliveira, M. D. C., Muccillo-Baisch, A. L., Yurgel, V. C., Buttini, F., Soares, F. A. A., Cordeiro, L. M., et al. (2022) · Nanomaterials · doi:10.3390/nano12071073 · Cited by 39
“Polyphenols are substances that present antioxidant properties as a consequence of their free radical scavenging action and metal chelating ability, preventing the enzymatic production of reactive oxygen species catalyzed by metals and thus displaying neuroprotective effects [1].”
BackgroundKupershmidt, L., & Youdim, M. B. H. (2023) · Cells · doi:10.3390/cells12050763 · Cited by 38
Self-citationEvaluation of the total oxy-radical scavenging capacity of catechins isolated from green tea
Kang, K. W., Oh, S. J., Ryu, S. Y., Song, G., Kim, B.-H., Kang, J. S., & Kim, S. K. (2010) · Food Chemistry · doi:10.1016/j.foodchem.2010.01.055 · Cited by 32
Goswami, D., Machini, M. T., Silvestre, D. M., Nomura, C. S., & Espósito, B. P. (2014) · Bioconjugate Chemistry · doi:10.1021/bc5004197 · Cited by 34
3-Hydroxypyridinone Derivatives as Metal-Sequestering Agents for Therapeutic Use
Santos, M. A., & Chaves, S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.162 · Cited by 31
Protein Phosphatase 2A as a Drug Target in the Treatment of Cancer and Alzheimer’s Disease
Wei, H., Zhang, H., Xie, J., Meng, D., Wang, X., Ke, D., Zeng, J., & Liu, R. (2020) · Current Medical Science · doi:10.1007/s11596-020-2140-1 · Cited by 31
Youdim, M. B. H. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70047-5 · Cited by 29
“This strategy relies on accumulating evidence, suggesting that neuronal death in the central nervous system (CNS) is often intimately linked to cellular processes that normally occur only during a mitotic cell cycle [33,34].”
BackgroundSelf-citationYoudim, M. B. H., & Oh, Y. J. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.3.167 · Cited by 29
“The novel multifunctional iron chelator, M30 was found to confer potential neuroprotective effects in preclinical neurodegenerative models with distinct etiologies, exerting selective iron chelation potency (compared with zinc and copper), radical scavenging, and inhibition of iron-induced membrane lipid peroxidation…”
BackgroundSelf-citationZheng, H., Fridkin, M., & Youdim, M. B. H. (2010) · Neurochemical Research · doi:10.1007/s11064-010-0293-1 · Cited by 29
“In order to design such new drugs, we started from three FDAapproved drugs (rivastigmine, donepezil and rasagiline) and our newly developed multifunctional chelator HLA20 or (5-[4-propargylpiperazin-1-ylmethyl]-8-hydroxyquinoline [19–21].”
BackgroundSelf-citationFouad, G. I., & Rizk, M. Z. (2019) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-019-0149-z · Cited by 34
Benkler, C., Offen, D., Melamed, E., Kupershmidt, L., Amit, T., Mandel, S. A., Youdim, M. B. H., & Weinreb, O. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0026-1 · Cited by 24
“Thus, an inhibitory effect of the novel iron-chelator compounds on cell cycle reentry [33], may trigger the process of differentiation through various iron-associated biological events [63].”
BackgroundSelf-citationAlzheimer's disease: In silico study of rosemary diterpenes activities
Abbaoui, Z., Merzouki, M., Oualdi, I., Bitari, A., Oussaid, A., Challioui, A., Touzani, R., Hammouti, B., & Diño, W. A. (2024) · Current Research in Toxicology · doi:10.1016/j.crtox.2024.100159 · Cited by 24
“Metals, particularly zinc, copper, and iron, also play a crucial role in the field of neuroscience, especially concerning Alzheimer ’ s disease, where they can influence the disease ’ s pathology (Amit et al., 2008; Barnham and Bush, 2008; Das et al., 2021).”
Shervedani, R. K., Rezvaninia, Z., Sabzyan, H., & Boeini, H. Z. (2014) · Analytica Chimica Acta · doi:10.1016/j.aca.2014.03.041 · Cited by 20
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 19
Pure Polyphenols Applications for Cardiac Health and Disease
dos Santos, C. N., Gomes, A., Oudot, C., Dias‐Pedroso, D., Rodriguez‐Mateos, A., Vieira, H. L. A., & Brenner, C. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180608102344 · Cited by 21
Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
Mashal, Y., Abdelhady, H. G., & Iyer, A. K. (2022) · Biomolecules · doi:10.3390/biom12071001 · Cited by 22
“found success in novel compounds that are specifically and rationally designed to cross the BBB and target multiple mechanisms underlying the specific neurodegenerative processes of AD [26].”
BackgroundMolecular medicine in ophthalmic care
RICHER, S. P., Stiles, W. R., & Thomas, C. (2009) · Optometry · doi:10.1016/j.optm.2009.03.018 · Cited by 17
“The use of iron-chelating polyphenolic molecules has been proposed as an intervention that addresses a wide range of age-related diseases such as Alzheimer’s, Parkinson’s, cardiovascular, and immune-compromised disease.(49) The hope is that via molecular medicine, true prevention via inhibition of lipofuscin can be re…”
BackgroundRadwan, A. A., Alanazi, F. K., & Raish, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286195 · Cited by 13
“M30, HLA-20 (8-hydroxyquinoline derivatives) [26, 27], and quercetin analogues (polyphenol flavonoids) (Fig 2) showed the most action in terms of iron chelation, radical scavenging, and inhibiting iron-catalyzed lipid membrane peroxidation [28].”
BackgroundBiometals and Alzheimer’s Disease
Mot, A. I., & Crouch, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804562-6.00001-4 · Cited by 16
Youdim, M. B. H. (2010) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10011 · Cited by 12
Self-citationYoudim, M. B. H. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02462-z · Cited by 10
“M30 is also a neuroprotective-neurorestorative chelator with the capacities of modulating APP regulation, Aβ reduction, and inhibiting Aβ aggregation induced by metal (Cu and Zn) ions (Gal et al. 2005; Zheng et al. 2005a, b, c, d; Zheng et al. 2005a, b, c, d; Zhu et al. 2007; Amit et al. 2008).”
BackgroundSelf-citationCombination Drug Therapy for the Treatment of Alzheimer’s Disease
Alvarez, X. A., Linares, C., & Masliah, E. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.92 · Cited by 9
Öztürk, Y., & Öztürk, N. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191014165633 · Cited by 9
Structural fingerprinting of pleiotropic flavonoids for multifaceted Alzheimer's disease
Punmiya, A., & Prabhu, A. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105486 · Cited by 9
Metadata
- Authors
- Amit, T., Avramovich‐Tirosh, Y., Youdim, M. B. H., & Mandel, S.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- ORCID
- Youdim, Moussa B. H.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-11-29
- Volume
- 22
- Issue
- 5
- Pages
- 1296-1305
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2072788211
- Cited by
- 126
- References
- 89
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 5 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 6 · 2013: 9 · 2012: 12
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
- Keywords
- Alzheimer's disease, iron chelators, brain iron homeostasis, neuroprotection, neurorestoration, oxidative stress, neuroinflammation, amyloid deposition, tau phosphorylation, neuronal apoptosis, iron-responsive element, amyloid precursor protein, polyphenols, disease-modifying therapy
- MeSH terms
- Alzheimer Disease, Animals, Brain, Catechin, Cell Cycle, Humans, Hydroxyquinolines, Iron, Iron Chelating Agents, Piperazines, Amyloid beta-Protein Precursor, PC12 Cells, Neuroprotective Agents, Neurodegenerative Diseases, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.